ArticleDisease models & mechanisms2014
Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition.
Article in Disease models & mechanisms, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- Strategies to mitigate muscle mass loss in individuals with spinal cord injury.The journal of spinal cord medicine · 2026Review
- Regular Exercise with Panax Ginseng Supplementation Attenuates Arsenic-Induced Muscular Weakness and Neurobehavioral Changes in Mice.Neurotoxicity research · 2025Article
- Chestnut (Nutrients · 2025Article
- Curcumin Mitigates Muscle Atrophy Potentially by Attenuating Calcium Signaling and Inflammation in a Spinal Nerve Ligation Model.Current issues in molecular biology · 2024Article
- Sexual dimorphisms in skeletal muscle: current concepts and research horizons.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Review
- Effects of hindlimb unloading on the mevalonate and mechanistic target of rapamycin complex 1 signaling pathways in a fast-twitch muscle in rats.Physiological reports · 2024Article
- Inhibiting myostatin signaling partially mitigates structural and functional adaptations to hindlimb suspension in mice.NPJ microgravity · 2023Article
- Delayed denervation-induced muscle atrophy inFrontiers in physiology · 2023Article
- Functional Nutrients to Ameliorate Neurogenic Muscle Atrophy.Metabolites · 2022Review
- Nerve-dependent distribution of subsynaptic type 1 inositol 1,4,5-trisphosphate receptor at the neuromuscular junction.The Journal of general physiology · 2022Article
- Article
- In Vivo Metabolic Responses to Different Formulations of Amino Acid Mixtures for the Treatment of Phenylketonuria (PKU).International journal of molecular sciences · 2022Article
- The role of mTORC1 in the regulation of skeletal muscle mass.Faculty reviews · 2022Review
- Angiotensin 1-7 prevents the excessive force loss resulting from 14- and 28-day denervation in mouse EDL and soleus muscle.The Journal of general physiology · 2021Article
- Pharmacologic approaches to prevent skeletal muscle atrophy after spinal cord injury.Current opinion in pharmacology · 2021Review
- Natural Compounds Attenuate Denervation-Induced Skeletal Muscle Atrophy.International journal of molecular sciences · 2021Review
- The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability.Physiological reports · 2021Article
- Wide Pulse Width Electroacupuncture Ameliorates Denervation-Induced Skeletal Muscle Atrophy in Rats via IGF-1/PI3K/Akt Pathway.Chinese journal of integrative medicine · 2021Article
- mTORC1 mediates fiber type-specific regulation of protein synthesis and muscle size during denervation.Cell death discovery · 2021Article
- Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The purpose of our study was to compare two acquired muscle atrophies and the use of myostatin inhibition for their treatment. Myostatin naturally inhibits skeletal muscle growth by binding to ActRIIB, a receptor on the cell surface of myofibers. Because blocking myostatin in an adult wild-type mouse induces profound muscle hypertrophy, we applied a soluble ActRIIB receptor to models of disuse (limb immobilization) and denervation (sciatic nerve resection) atrophy. We found that treatment of immobilized mice with ActRIIB prevented the loss of muscle mass observed in placebo-treated mice. Our results suggest that this protection from disuse atrophy is regulated by serum and glucocorticoid-induced kinase (SGK) rather than by Akt. Denervation atrophy, however, was not protected by ActRIIB treatment, yet resulted in an upregulation of the pro-growth factors Akt, SGK and components of the mTOR pathway. We then treated the denervated mice with the mTOR inhibitor rapamycin and found that, despite a reduction in mTOR activation, there is no alteration of the atrophy phenotype. Additionally, rapamycin prevented the denervation-induced upregulation of the mTORC2 substrates Akt and SGK. Thus, our studies show that denervation atrophy is not only independent from Akt, SGK and mTOR activation but also has a different underlying pathophysiological mechanism than disuse atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.